New Blood‑Based Alzheimer’s Test at Zydus Hospitals, Ahmedabad
On 19 June 2026, Zydus Hospitals in Ahmedabad announced the launch of a dedicated Alzheimer’s testing facility, the first of its kind in Gujarat. The centre offers a blood‑based biomarker assay that measures the p‑Tau217/Aβ42 ratio, delivering approximately 95 % specificity and 91 % sensitivity for detecting Alzheimer’s disease (AD). The assay correlates strongly with amyloid PET imaging and cerebrospinal fluid (CSF) findings, outperforming many conventional biomarkers and providing a less invasive alternative to lumbar puncture.
The press release highlighted that more than 55 million people worldwide live with dementia (WHO, 2024) and that India had an estimated 6.5‑8 million dementia patients in 2025. The risk of dementia rises sharply after age 60, roughly doubling every few years, making early detection critical.
Senior neurologist Dr. Ajit Sowani explained that newly approved anti‑amyloid drugs can slow neurological decline by 25‑35 % in patients with mild cognitive impairment (MCI) and early AD, emphasizing the importance of confirming diagnosis early through clinical, radiological, and biomarker assessments. He noted that the blood test is easier to administer than CSF tests but cautioned that the drugs have modest benefits and notable side‑effects, requiring strict patient‑selection criteria. He also recommended lifestyle measures such as quality sleep, regular exercise, stress reduction, learning new skills, and social interaction for elderly mental health.
Dr. Arvind Sharma, another senior neurologist, added that two anti‑amyloid drugs have received FDA approval and that early‑stage use can decelerate disease progression, provided intervention occurs before significant brain atrophy. He reiterated the role of aerobic exercise, “neurobics,” language learning, musical training, puzzles, and varied daily routines in preserving cognitive function.
Dr. Jayesh Trivedi, senior pathologist, emphasized that the p‑Tau217 component is highly specific to Alzheimer’s disease and that the p‑Tau217/Aβ42 ratio yields extremely precise diagnostic results, closely mirroring PET and CSF outcomes.
The announcement also outlined Zydus Hospitals’ comprehensive Neurosciences programme, which brings together a multidisciplinary team of neurologists—Dr. Ajit Sowani, Dr. Arvind Sharma, Dr. Dinesh Saini, Dr. Hetal Parikh, Dr. Nikhil Dave, Dr. Bhargesh Patel, Dr. Vishwajeet Raj—and neurosurgeons—Dr. Dipak Patel, Dr. Kalpesh Shah, Dr. Yagneshkumar Saija, Dr. Ravi Chauhan, Dr. Vandan Raiyani, Dr. Anand Shah, and Dr. Vignesh Gopalarathinam. The programme’s strengths include management of brain and spinal tumours, stroke care, and a full spectrum of neurological disorders such as Parkinson’s disease, epilepsy, headaches, migraine, vertigo, demyelination, dementia, Alzheimer’s disease, and neuro‑oncology.
Further information about the services is available at https://zydushospitals.com/. The release includes the hospital’s logo (https://mma.prnewswire.com/media/2975690/5987421/ZydusHospitalLogo.jpg) and notes that the content is provided under an arrangement with PRNewswire, with PTI assuming no editorial responsibility.